亞伯氏症候群（AS）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 法國市場預計將從約 170 萬美元成長到約 230 萬美元（年複合成長率約 3%）。
• 儘管由於缺乏疾病修正治療導致成長仍然有限，但正在研發中的創新正在推動未來的成長潛力。

亞伯氏症候群概述

亞伯氏症候群是一種罕見的、進行性遺傳基底膜疾病，由編碼IV型膠原蛋白α-3、α-4和α-5鏈的COL4A3、COL4A4或COL4A5基因的致病突變所引起。此疾病最常見的遺傳模式為X連鎖遺傳，導致腎絲球基底膜（GBM）、耳蝸和眼部組織出現結構缺陷。

膠原蛋白網路的破壞會導致一組特徵性的三聯徵：進行性感音性聽障、眼部異常（尤其是前部晶狀體錐體）和血尿性腎臟病。腎臟疾病始於鏡下血尿和蛋白尿，並隨著時間的推移進展至末期腎功能衰竭（ESRD）。

診斷方法正從傳統的切片檢查觀察（例如腎小球基底膜分層和「籃狀」有絲分裂）轉向分子遺傳學檢測。目前尚無針對潛在基因缺陷的治療方法，治療主要集中於早期使用腎素-血管緊張素-醛固酮系統阻斷劑（血管緊張素轉換酶抑制劑/血管緊張素受體阻斷劑）進行腎臟保護，並擴大使用SGLT2抑制劑來延緩腎功能進展。針對纖維化和內皮素路徑的新治療方法目前正在研究中。

主要亮點

• 亞伯氏症候群是一種進行性的、遺傳性的腎臟疾病，會影響多個器官。
• 預計法國患有該疾病的人數將從約 9,800 人增加到約 12,300 人（年均複合成長率約 2.3%）。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Enyo Pharma
• Calliditas Therapeutics AB
• Eloxx Pharmaceuticals, Inc.
• Biogen
• Bayer
• River 3 Renal Corp.
• Novartis Pharmaceuticals

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
• 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Alport Syndrome Market Outlook

Thelansis's "Alport Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alport Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Alport Syndrome Overview

Alport syndrome is a rare, progressive hereditary disorder of basement membranes caused by pathogenic mutations in the COL4A3, COL4A4, or COL4A5 genes, which encode the alpha-3, alpha-4, and alpha-5 chains of type IV collagen. The disease most commonly follows an X-linked inheritance pattern, leading to structural defects in the glomerular basement membrane (GBM), cochlea, and ocular tissues.

This disruption of the collagen network results in a characteristic clinical triad of progressive sensorineural hearing loss, ocular abnormalities (notably anterior lenticonus), and hematuric nephropathy. The renal disease progresses from microhematuria and proteinuria to end-stage renal disease (ESRD) over time.

Diagnosis has shifted toward molecular genetic testing, replacing traditional renal biopsy findings such as GBM lamellation and "basket-weave" splitting. Currently, there are no therapies that correct the underlying genetic defect, and management focuses on early nephroprotection, primarily through RAAS blockade (ACE inhibitors/ARBs), with increasing use of SGLT2 inhibitors to delay renal progression. Emerging therapies targeting fibrosis and endothelin pathways are under investigation.

Key Highlights

• Alport syndrome is a rare, progressive genetic renal disorder with multisystem involvement
• France prevalence expected to increase from ~9.8K to ~12.3K (~2.3% CAGR)

Market Overview

• France market projected to grow from ~$1.7M to ~$2.3M (~3% CAGR)
• Growth remains limited due to lack of disease-modifying therapies, with pipeline innovation driving future potential

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Enyo Pharma
• Calliditas Therapeutics AB
• Eloxx Pharmaceuticals, Inc.
• Biogen
• Bayer
• River 3 Renal Corp.
• Novartis Pharmaceuticals

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)